Javascript must be enabled to continue!
Ataxia in Multiple Sclerosis: From Current Understanding to Therapy
View through CrossRef
Ataxia is a type of neurological disorder that affects the ability to coordinate voluntary movements, such as walking, balance, and speech. In people with multiple sclerosis (MS), ataxia is a common symptom, affecting around 80% of people with the condition. The cause of ataxia in MS is still unknown; however, it is thought to be due to damage to the part of the central nervous system (CNS) that controls balance, coordination, and movement, especially the cerebellum. Symptoms of ataxia in people with MS can range from mild to severe, and can include a lack of coordination, difficulty speaking, difficulty walking, and gait. Ataxia management in MS typically involves pharmacotherapy to improve coordination, physiotherapy to enhance strength and balance, surgical procedures to alleviate tremor as well as occupational therapy to help with everyday activities.
Title: Ataxia in Multiple Sclerosis: From Current Understanding to Therapy
Description:
Ataxia is a type of neurological disorder that affects the ability to coordinate voluntary movements, such as walking, balance, and speech.
In people with multiple sclerosis (MS), ataxia is a common symptom, affecting around 80% of people with the condition.
The cause of ataxia in MS is still unknown; however, it is thought to be due to damage to the part of the central nervous system (CNS) that controls balance, coordination, and movement, especially the cerebellum.
Symptoms of ataxia in people with MS can range from mild to severe, and can include a lack of coordination, difficulty speaking, difficulty walking, and gait.
Ataxia management in MS typically involves pharmacotherapy to improve coordination, physiotherapy to enhance strength and balance, surgical procedures to alleviate tremor as well as occupational therapy to help with everyday activities.
Related Results
Narrative review based on fingolimod therapy in pediatric MS
Narrative review based on fingolimod therapy in pediatric MS
The course of pediatric-onset multiple sclerosis and adult multiple sclerosis shows some clinical differences. The rate of having a second attack after the first clinical event is ...
Recent Advances in Multiple Sclerosisi Research
Recent Advances in Multiple Sclerosisi Research
The chronic autoimmune disease known as multiple sclerosis (MS) is characterized by inflammation, demyelination, loss of neurons, and gliosis (scarring). Our object to review MS pa...
Gait training with a wearable curara® robot for cerebellar ataxia: a single-arm study
Gait training with a wearable curara® robot for cerebellar ataxia: a single-arm study
Abstract
Background: Ataxic gait is one of the most common and problematic symptoms in people with degenerative cerebellar ataxia. Intensive and well-coordinated inpatient ...
Gait training with a wearable curara® robot for cerebellar ataxia: a single-arm study
Gait training with a wearable curara® robot for cerebellar ataxia: a single-arm study
Abstract
Background
Ataxic gait is one of the most common and disabling symptoms in people with degenerative cerebellar ataxia. Intensive and well-c...
OCT based evaluation of retinal changes in multiple sclerosis
OCT based evaluation of retinal changes in multiple sclerosis
Background: Optical coherence tomography is a non-invasive imaging technique routinely used in ophthalmology to visualize and quantify the layers of the retina. It also provides in...
Accuracy of MRI criteria for dissemination in space for the diagnosis of multiple sclerosis in patients with clinically isolated syndromes
Accuracy of MRI criteria for dissemination in space for the diagnosis of multiple sclerosis in patients with clinically isolated syndromes
The MRI Barkhof—Tintoré criteria have proved to be highly specific for predicting conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome...
Meta‐analysis of the use of Ofatumumab in the treatment of relapsing‐remitting multiple sclerosis
Meta‐analysis of the use of Ofatumumab in the treatment of relapsing‐remitting multiple sclerosis
AbstractBackgroundOfatumumab is the first monoclonal antibody developed specifically for treating relapsed multiple sclerosis (RMS). This disease (Multiple Sclerosis) includes rela...
Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment
Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment
Multiple sclerosis is a progressive demyelinating central nervous system disorder with unknown etiology. The condition has heterogeneous presentations, including relapsing-remittin...

